Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMEC-5: Timing of Local Treatment in Oligometastatic Esophageal or Gastric Cancer
NCT07000253Phase 2Recruiting
- Sponsor
- University of Amsterdam
- Start
- Apr 2026
- Primary completion
- Nov 2031
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in esophageal cancer, gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by University of Amsterdam. Primary endpoint: Progression-Free Survival at 53 months. Started Apr 2026; status: recruiting.
02
Conditions
esophageal cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07000253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000253.